349 related articles for article (PubMed ID: 30415479)
21. History of Erythropoiesis-Stimulating Agents, the Development of Biosimilars, and the Future of Anemia Treatment in Nephrology.
Kalantar-Zadeh K
Am J Nephrol; 2017; 45(3):235-247. PubMed ID: 28142147
[TBL] [Abstract][Full Text] [Related]
22. Biosimilars: A consideration of the regulations in the United States and European union.
Daller J
Regul Toxicol Pharmacol; 2016 Apr; 76():199-208. PubMed ID: 26732800
[TBL] [Abstract][Full Text] [Related]
23. Insights of biosimilars through SWOT analysis.
Patel MM; Shah PJ; Patel BM
Expert Opin Biol Ther; 2014 Feb; 14(2):139-44. PubMed ID: 24151903
[No Abstract] [Full Text] [Related]
24. Differentiating biosimilarity and comparability in biotherapeutics.
Azevedo V; Hassett B; Fonseca JE; Atsumi T; Coindreau J; Jacobs I; Mahgoub E; O'Brien J; Singh E; Vicik S; Fitzpatrick B
Clin Rheumatol; 2016 Dec; 35(12):2877-2886. PubMed ID: 27734233
[TBL] [Abstract][Full Text] [Related]
25. Developing the Totality of Evidence for Biosimilars: Regulatory Considerations and Building Confidence for the Healthcare Community.
Markus R; Liu J; Ramchandani M; Landa D; Born T; Kaur P
BioDrugs; 2017 Jun; 31(3):175-187. PubMed ID: 28439817
[TBL] [Abstract][Full Text] [Related]
26. BIOSIMILARS AND NEW INSULIN VERSIONS.
Peters AL; Pollom RD; Zielonka JS; Carey MA; Edelman SV
Endocr Pract; 2015 Dec; 21(12):1387-94. PubMed ID: 26340139
[TBL] [Abstract][Full Text] [Related]
27. The comparability conundrum: biosimilars in the United States, Europe and Canada.
Courage N; Parsons A
Food Drug Law J; 2011; 66(2):203-24, i-ii. PubMed ID: 24505840
[TBL] [Abstract][Full Text] [Related]
28. An industry update: the latest developments in therapeutic delivery.
Simpson I
Ther Deliv; 2018 Jan; 9(1):9-15. PubMed ID: 29216806
[TBL] [Abstract][Full Text] [Related]
29. Biosimilars: Rationale and current regulatory landscape.
Olech E
Semin Arthritis Rheum; 2016 Apr; 45(5 Suppl):S1-10. PubMed ID: 26947438
[TBL] [Abstract][Full Text] [Related]
30. Biosimilars in the Treatment of Retinal Disease in the United States.
Vakharia PS; Eichenbaum DA; Baumal CR
Ophthalmic Surg Lasers Imaging Retina; 2023 Jun; 54(6):362-366. PubMed ID: 37222553
[TBL] [Abstract][Full Text] [Related]
31. Recognizing and addressing challenges to the adoption of trastuzumab biosimilars and HER2-targeted therapies.
Whalen J
Am J Manag Care; 2020 Mar; 26(2 Suppl):S23-S31. PubMed ID: 32282172
[TBL] [Abstract][Full Text] [Related]
32. Barriers To US Biosimilar Market Growth: Lessons From Biosimilar Patent Litigation.
Van de Wiele VL; Kesselheim AS; Sarpatwari A
Health Aff (Millwood); 2021 Aug; 40(8):1198-1205. PubMed ID: 34339242
[TBL] [Abstract][Full Text] [Related]
33. The challenge of indication extrapolation for infliximab biosimilars.
Feagan BG; Choquette D; Ghosh S; Gladman DD; Ho V; Meibohm B; Zou G; Xu Z; Shankar G; Sealey DC; Russell AS
Biologicals; 2014 Jul; 42(4):177-83. PubMed ID: 24962198
[TBL] [Abstract][Full Text] [Related]
34. The Language of Biosimilars: Clarification, Definitions, and Regulatory Aspects.
Declerck P; Danesi R; Petersel D; Jacobs I
Drugs; 2017 Apr; 77(6):671-677. PubMed ID: 28258517
[TBL] [Abstract][Full Text] [Related]
35. Biosimilars for Rheumatoid Arthritis: Don't Count Them Out Quite Yet.
Rychlick N
Manag Care; 2018 Jan; 27(1):29. PubMed ID: 29369768
[TBL] [Abstract][Full Text] [Related]
36. Opportunities and challenges in biosimilar uptake in oncology.
Dolan C
Am J Manag Care; 2018 Jun; 24(11 Suppl):S237-S243. PubMed ID: 29957909
[TBL] [Abstract][Full Text] [Related]
37. Comparing Onset of Biosimilar Versus Generic Competition in the United States.
Beall RF; Ronksley PE; Wick J; Darrow JJ; Sarpatwari A; Kesselheim AS
Clin Pharmacol Ther; 2020 Dec; 108(6):1308-1314. PubMed ID: 32621540
[TBL] [Abstract][Full Text] [Related]
38. A Decade of FDA-Approved Drugs (2010-2019): Trends and Future Directions.
Brown DG; Wobst HJ
J Med Chem; 2021 Mar; 64(5):2312-2338. PubMed ID: 33617254
[TBL] [Abstract][Full Text] [Related]
39. First US biosimilar edges towards market.
Senior M
Nat Biotechnol; 2015 Mar; 33(3):222-3. PubMed ID: 25748898
[No Abstract] [Full Text] [Related]
40. Examining Manufacturing Readiness for Breakthrough Drug Development.
Dye E; Sturgess A; Maheshwari G; May K; Ruegger C; Ramesh U; Tan H; Cockerill K; Groskoph J; Lacana E; Lee S; Miksinski SP
AAPS PharmSciTech; 2016 Jun; 17(3):529-38. PubMed ID: 26608693
[No Abstract] [Full Text] [Related]
[Previous] [Next] [New Search]
